140 related articles for article (PubMed ID: 38053565)
1. Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia.
Aust Prescr; 2023 Aug; 46(2):40-41. PubMed ID: 38053565
[No Abstract] [Full Text] [Related]
2. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Reagan PM; Friedberg JW
Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
[TBL] [Abstract][Full Text] [Related]
3. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma.
Anderson MK; Torosyan A; Halford Z
Ann Pharmacother; 2022 May; 56(5):609-619. PubMed ID: 34340597
[TBL] [Abstract][Full Text] [Related]
4. In brief: Brexucabtagene autoleucel (Tecartus) for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 2023 Jun; 65(1678):e105-e106. PubMed ID: 37339099
[No Abstract] [Full Text] [Related]
5. FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Bouchkouj N; Lin X; Wang X; Przepiorka D; Xu Z; Purohit-Sheth T; Theoret M
Oncologist; 2022 Oct; 27(10):892-899. PubMed ID: 35983953
[TBL] [Abstract][Full Text] [Related]
6. [New European approval: Brexucabtagene autoleucel in adult relapsed/refractory acute lymphoblastic leukemia].
Lemoine J; Marchand T
Bull Cancer; 2022 Dec; 109(12):1232-1233. PubMed ID: 36270817
[No Abstract] [Full Text] [Related]
7. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
Deshpande A; Wang Y; Munoz J; Jain P
Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
[TBL] [Abstract][Full Text] [Related]
8. Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
Frey NV
Blood; 2022 Jul; 140(1):11-15. PubMed ID: 35507688
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
Jain P; Nastoupil L; Westin J; Lee HJ; Navsaria L; Steiner RE; Ahmed S; Moghrabi O; Oriabure O; Chen W; Badillo M; Flowers CR; Wang ML
Br J Haematol; 2021 Jan; 192(2):e38-e42. PubMed ID: 33152104
[No Abstract] [Full Text] [Related]
10. Top advances of the year: Leukemia.
Kent A; Pollyea DA
Cancer; 2023 Apr; 129(7):981-985. PubMed ID: 36585394
[TBL] [Abstract][Full Text] [Related]
11. Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma.
Aydilek E; Klein-Scory S; Thomson J; Nilius-Eliliwi V; Vangala D; Schroers R; Wulf G; Mika T
Hemasphere; 2023 Sep; 7(9):e949. PubMed ID: 37654738
[No Abstract] [Full Text] [Related]
12. Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis.
Khurana A; Dalland JC; Young JR; Inwards DJ; Paludo J
Am J Hematol; 2021 Aug; 96(8):E298-E301. PubMed ID: 33984157
